The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME* trial

Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME* trial
Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME* trial
Summary Background & aims Non-alcoholic fatty liver disease (NAFLD) is a liver condition characterised by liver fat accumulation and often considered to be the liver manifestation of metabolic syndrome. The aim of this study was to examine in patients with NAFLD the system-wide effects of treatment with docosahexaenoic acid + eicosapentaenoic acid (DHA + EPA) versus placebo on the plasma proteome. Methods Plasma from patients that participated in a 15–18 months randomised, double-blind placebo-controlled trial testing the effects of 4 g DHA + EPA daily was analysed using depletion-free quantitative proteomics. Results Bioinformatics interpretation of the proteomic analysis showed that DHA + EPA treatment affected pathways involving blood coagulation, immune/inflammatory response and cholesterol metabolism (p < 0.05). Two key proteins of cardiovascular risk, prothrombin and apolipoprotein B-100, were shown to decrease as a result of DHA + EPA supplementation [Prothrombin: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.13 (0.20) p = 0.05, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.48 (0.35) p = 0.03; Apo B-100: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.24 (0.16) p = 0.01, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.15 (0.05) p = 0.02]. Conclusions Plasma proteomics applied in a randomised, placebo-controlled trial showed that high dose DHA + EPA treatment in patients with NAFLD affects multiple pathways involved in chronic non-communicable diseases.
0261-5614
1952-1955
Manousopoulou, Antigoni
9a5e4e75-cea9-4d0b-91c8-0fa2af02632f
Scorletti, Eleonora
42bb0659-ac67-4a73-bf36-a881fe6c1563
Smith, Deborah
b41c2f97-269c-4a50-ba95-830e823cc7df
Teng, Jie
aa0dac71-baf9-499f-9bd4-593e917c9c8c
Fotopoulos, Miltiadis
05714262-55c5-48a7-af57-397d5dd1cd6a
Roumeliotis, Theodoros I.
f1284c98-b5eb-483e-9416-594c678e62fd
Clough, Geraldine F.
9f19639e-a929-4976-ac35-259f9011c494
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd
Manousopoulou, Antigoni
9a5e4e75-cea9-4d0b-91c8-0fa2af02632f
Scorletti, Eleonora
42bb0659-ac67-4a73-bf36-a881fe6c1563
Smith, Deborah
b41c2f97-269c-4a50-ba95-830e823cc7df
Teng, Jie
aa0dac71-baf9-499f-9bd4-593e917c9c8c
Fotopoulos, Miltiadis
05714262-55c5-48a7-af57-397d5dd1cd6a
Roumeliotis, Theodoros I.
f1284c98-b5eb-483e-9416-594c678e62fd
Clough, Geraldine F.
9f19639e-a929-4976-ac35-259f9011c494
Calder, Philip C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd

Manousopoulou, Antigoni, Scorletti, Eleonora, Smith, Deborah, Teng, Jie, Fotopoulos, Miltiadis, Roumeliotis, Theodoros I., Clough, Geraldine F., Calder, Philip C., Byrne, Christopher D. and Garbis, Spiros D. (2019) Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME* trial. Clinical Nutrition, 38 (4), 1952-1955. (doi:10.1016/j.clnu.2018.07.037).

Record type: Article

Abstract

Summary Background & aims Non-alcoholic fatty liver disease (NAFLD) is a liver condition characterised by liver fat accumulation and often considered to be the liver manifestation of metabolic syndrome. The aim of this study was to examine in patients with NAFLD the system-wide effects of treatment with docosahexaenoic acid + eicosapentaenoic acid (DHA + EPA) versus placebo on the plasma proteome. Methods Plasma from patients that participated in a 15–18 months randomised, double-blind placebo-controlled trial testing the effects of 4 g DHA + EPA daily was analysed using depletion-free quantitative proteomics. Results Bioinformatics interpretation of the proteomic analysis showed that DHA + EPA treatment affected pathways involving blood coagulation, immune/inflammatory response and cholesterol metabolism (p < 0.05). Two key proteins of cardiovascular risk, prothrombin and apolipoprotein B-100, were shown to decrease as a result of DHA + EPA supplementation [Prothrombin: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.13 (0.20) p = 0.05, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.48 (0.35) p = 0.03; Apo B-100: Males DHA + EPA Mean iTRAQ log2ratio (SD) = −0.24 (0.16) p = 0.01, Females DHA + EPA Mean iTRAQ log2ratio (SD) = −0.15 (0.05) p = 0.02]. Conclusions Plasma proteomics applied in a randomised, placebo-controlled trial showed that high dose DHA + EPA treatment in patients with NAFLD affects multiple pathways involved in chronic non-communicable diseases.

Text
30 MAY 18 Manousopoulou A et al Clin Nutr clean - Accepted Manuscript
Download (109kB)
Image
NAFLD Figure 1 - Accepted Manuscript
Download (3MB)
Text
Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease - Plasma proteomics in the randomized WELCOME trial Clin Nutr Manousopoulou et al 2018 - Version of Record
Download (689kB)

More information

Accepted/In Press date: 1 August 2018
e-pub ahead of print date: 17 August 2018
Published date: 1 August 2019

Identifiers

Local EPrints ID: 424794
URI: http://eprints.soton.ac.uk/id/eprint/424794
ISSN: 0261-5614
PURE UUID: 8b90cc37-ff78-4738-8eaf-bfc34cc7f2cf
ORCID for Geraldine F. Clough: ORCID iD orcid.org/0000-0002-6226-8964
ORCID for Philip C. Calder: ORCID iD orcid.org/0000-0002-6038-710X
ORCID for Christopher D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753
ORCID for Spiros D. Garbis: ORCID iD orcid.org/0000-0002-1050-0805

Catalogue record

Date deposited: 05 Oct 2018 11:46
Last modified: 22 Nov 2021 06:46

Export record

Altmetrics

Contributors

Author: Antigoni Manousopoulou
Author: Eleonora Scorletti
Author: Deborah Smith
Author: Jie Teng
Author: Miltiadis Fotopoulos
Author: Theodoros I. Roumeliotis
Author: Spiros D. Garbis ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×